

**AMENDMENT**


Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

**IN THE CLAIMS:**

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-66. (Cancelled)

67. (Currently amended) A method of inhibiting steroid sulphatase activity comprising administering, a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase to a patient in need of inhibition of steroid sulphatase activity by a non-oestrogenic sulphamate compound ~~lacking oestrogenic activity~~, wherein the non-oestrogenic sulphamate compound is a sulphamate compound having Formula IV;




Formula IV

wherein

one of R<sub>1</sub> and R<sub>2</sub> is H and the other of R<sub>1</sub> and R<sub>2</sub> is a substituent other than H or R<sub>1</sub> and R<sub>2</sub> may be the same or different but not both being H, wherein the substituent other than H is alkyl, cycloalkyl, alkoxy, alkenyl, aryl, substituted alkyl, substituted cycloalkyl, substituted alkenyl, substituted aryl, a nitrogen containing group, a S containing group, or a carboxy containing group; wherein Y is a suitable linking group comprising one or more of C, O, N, and S; and each of R<sub>3</sub> and R<sub>4</sub> is independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, wherein at least one of R<sub>3</sub> and R<sub>4</sub> is H.

68. (Currently amended) A method of treating endocrine-dependent cancer comprising administering a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase, to a patient in need of treatment of endocrine-dependent cancer by a non-oestrogenic sulphamate compound ~~lacking oestrogenic activity~~, wherein the compound is a sulphamate compound having Formula IV;



Formula IV

wherein

one of R<sub>1</sub> and R<sub>2</sub> is H and the other of R<sub>1</sub> and R<sub>2</sub> is a substituent other than H or R<sub>1</sub> and R<sub>2</sub> may be the same or different but not both being H, wherein the substituent other than H is alkyl, cycloalkyl, alkoxy, alkenyl, aryl, substituted alkyl, substituted cycloalkyl, substituted alkenyl, substituted aryl, a nitrogen containing group, a S containing group, or a carboxy containing group;

Y is a suitable linking group comprising one or more of C, O, N, and S; and

each of R<sub>3</sub> and R<sub>4</sub> is independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, wherein at least one of R<sub>3</sub> and R<sub>4</sub> is H.

69. (Withdrawn) The method according to claim 67 wherein the substituent of R<sub>1</sub> and R<sub>2</sub> that is other than H is a C<sub>1-6</sub> alkyl, a C<sub>1-6</sub> cycloalkyl, a C<sub>1-6</sub> alkenyl, a substituted C<sub>1-6</sub> alkyl, a substituted C<sub>1-6</sub> cycloalkyl, a substituted C<sub>1-6</sub> alkenyl, a substituted aryl, a nitrogen containing group, a S containing group, or a carboxy group having from 1-6 carbon atoms.

70. (Withdrawn) The method according to claim 68 wherein the substituent of R<sub>1</sub> and R<sub>2</sub> that is other than H is a C<sub>1-6</sub> alkyl, a C<sub>1-6</sub> cycloalkyl, a C<sub>1-6</sub> alkenyl, a substituted C<sub>1-6</sub> alkyl, a substituted C<sub>1-6</sub> cycloalkyl, a substituted C<sub>1-6</sub> alkenyl, a substituted aryl, a nitrogen containing group, a S containing group, or a carboxy group having from 1-6 carbon atoms.

71. (Withdrawn) The method according to claim 69 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a  $C_{1-6}$  alkyl, a  $C_{1-6}$  alkenyl, a nitrogen containing group, or a carboxy group having from 1-6 carbon atoms.

72. (Withdrawn) The method according to claim 70 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a  $C_{1-6}$  alkyl, a  $C_{1-6}$  alkenyl, a nitrogen containing group, or a carboxy group having from 1-6 carbon atoms.

73. (Withdrawn) The method according to claim 71 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a is selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  alkenyl,  $NO_2$ , or a carboxy group having from 1-6 carbon atoms.

74. (Withdrawn) The method according to claim 72 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a is selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  alkenyl,  $NO_2$ , or a carboxy group having from 1-6 carbon atoms.

75. (Withdrawn) The method according to claim 73 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a  $C_3$  alkyl, a  $C_3$  alkenyl,  $NO_2$ , or  $H_3CO$ .

76. (Withdrawn) The method according to claim 74 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a  $C_3$  alkyl, a  $C_3$  alkenyl,  $NO_2$ , or  $H_3CO$ .

77. (Currently amended) The method according to claim 67 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is  $[[a]]$ an alkoxy group.

78. (Previously presented) The method according to claim 68 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a alkoxy group.

79. (Previously presented) The method according to claim 77 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a methoxy group.

80. (Previously presented) The method according to claim 78 wherein the substituent of  $R_1$  and  $R_2$  that is other than H is a methoxy group.

81. (Previously presented) The method according to claim 67 wherein the group A/ring B combination contains one or more alkoxy substituents.

82. (Previously presented) The method according to claim 68 wherein the group A/ring B combination contains one or more alkoxy substituents.

83. (Withdrawn) The method according to claim 67 wherein each of  $R_1$  and  $R_2$  is an alkoxy group.

84. (Withdrawn) The method according to claim 68 wherein each of  $R_1$  and  $R_2$  is an alkoxy group.

85. (Withdrawn) The method according to claim 83 wherein each of  $R_1$  and  $R_2$  is a methoxy group.

86. (Withdrawn) The method according to claim 85 wherein each of  $R_1$  and  $R_2$  is a methoxy group.

87. (Previously presented) The method according to claim 67 wherein at least one of  $R_3$  and  $R_4$  is H.

88. (Currently amended) The method according to ~~any one of claims~~ claim 68 wherein each of  $R_3$  and  $R_4$  is H.


89. (Currently amended) The method according to claim 67 wherein Y is  $-C(O)-$ .


90. (Currently amended) The method according to claim 68 wherein Y is  $-C(O)-$ .


91. (Currently amended) The method of claim 68 wherein the endocrine-dependent cancer is breast, ovarian, endometrial, or prostate cancer.


92. (Previously presented) The method of claim 91 wherein the endocrine-dependent cancer is breast cancer.

93. (Currently amended) A method of treating endocrine-dependent cancer comprising administering a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase to a patient in need of treatment of endocrine-dependent cancer by a non-oestrogenic sulphamate compound ~~lacking oestrogenic activity~~, wherein the compound has one of Formulae VI - IX

	R <sub>1</sub>	R <sub>2</sub>	Formula VI
	a) n- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	H	
	b) H	n-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	
	c) n- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	n-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	

	R <sub>1</sub>	R <sub>2</sub>	Formula VII
	a) - CH <sub>2</sub> CH=CH <sub>2</sub>	H	
	b) H	-CH <sub>2</sub> CH=CH <sub>2</sub>	
	c) - CH <sub>2</sub> CH=CH <sub>2</sub>	-CH <sub>2</sub> CH=CH <sub>2</sub>	


		R <sub>1</sub>	R <sub>2</sub>	Formula VIII
	a)	H <sub>3</sub> CO-	H	
	b)	H	H <sub>3</sub> CO-	
	c)	H <sub>3</sub> CO-	H <sub>3</sub> CO-	


		R <sub>1</sub>	R <sub>2</sub>	Formula IX
	a)	-NO <sub>2</sub>	H	
	b)	H	-NO <sub>2</sub>	
	c)	-NO <sub>2</sub>	-NO <sub>2</sub>	


94. (Currently amended) The method of claim 93 wherein the endocrine-dependent cancer is breast, ovarian, endometrial, or prostate cancer.


95. (Previously presented) The method of claim 94 wherein the endocrine-dependent cancer is breast cancer.

96. (Currently amended) A method of inhibiting steroid sulphatase activity comprising administering a non-oestrogenic sulphamate compound to a patient in need of inhibition of steroid sulphatase activity by a non-oestrogenic sulphamate compound, wherein the compound has one of Formulae VI - IX

		R <sub>1</sub>	R <sub>2</sub>	Formula VI
	a)	n- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	H	
	b)	H	n-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	
	c)	n- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	n-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	

		R <sub>1</sub>	R <sub>2</sub>	Formula VII
	a)	- CH <sub>2</sub> CH=CH <sub>2</sub>	H	
	b)	H	-CH <sub>2</sub> CH=CH <sub>2</sub>	
	c)	- CH <sub>2</sub> CH=CH <sub>2</sub>	-CH <sub>2</sub> CH=CH <sub>2</sub>	

		R <sub>1</sub>	R <sub>2</sub>	Formula VIII
	a)	H <sub>3</sub> CO-	H	
	b)	H	H <sub>3</sub> CO-	
	c)	H <sub>3</sub> CO-	H <sub>3</sub> CO-	

		R <sub>1</sub>	R <sub>2</sub>	Formula IX
	a)	-NO <sub>2</sub>	H	
	b)	H	-NO <sub>2</sub>	
	c)	-NO <sub>2</sub>	-NO <sub>2</sub>	